]>
IRCT20211228053553N1 IRCT 2022-01-09 Esfahan University of Medical Sciences Evaluation of the effect of Latanaprost in the treatment of androgenetic alopecia Comparison of the therapeutic effects of 5% Minoxidil solution alone with 5% Minoxidil solution and 0.005% Latanoprost in men with androgenetic alopecia 2021-12-30 anticipated 50 Complete https://irct.ir/trial/60932 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 50 eligible patients were selected and after studying the informed consent form; in a simple and individual random method with the help of random allocation software, each patient was assigned a number and divided into two groups by random allocation, Blinding description: The two solutions of minoxidil and the combined solution of latanoprost and minoxidil are already prepared by the pharmacist in the same volume and with the same color and shape, and are marked with codes A and B and will be given to the patients. Therefore, the patient and the researcher will not have any information about the two prescription solutions. 3 Androgenic alopecia. Intervention 1: Intervention group: Patients in the first intervention group consume 1.5 cc of minoxidil solution, each solution equivalent to 20 drops twice a day for 6 months. Intervention 2: Intervention group: Patients in the second intervention group consume a combination of latanoprost 0.005% and minoxidil 5% for 6 months. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information
public Nazila poostiyan
Hezar Jerib St., Al-Zahra Hospital, Dermatology Department
Isfahan Iran (Islamic Republic of) 8174675731 +98 31 3620 2020 N.poostiyan@med.mui.ac.ir Esfahan University of Medical Sciences scientific Nazila poostiyan
Hezar Jerib St., Al-Zahra Hospital, Dermatology Department
Isfahan Iran (Islamic Republic of) 8174675731 +98 31 3620 2020 N.poostiyan@med.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) Satisfaction of the patient and his family to participate in the study Confirmation of androgenetic alopecia by two experienced dermatologists based on Hamilton diagnostic criteria Age 18 to 45 years 2 to 5 hair loss severity according to Hamilton criteria The duration of hair loss is less than 10 years 18 years 45 years Male History or observation of allergies to any of the drugs Minoxidil and Latanoprost, history of heart disease and use of antihypertensive drugs Receiving systemic treatment for androgenic alopecia during the 6 months before the study of other types of alopecia such as alopecia areata, telogen effluvium, anagen effluvium scarring alopecia, any systemic skin disease L64.9 Androgenic alopecia, unspecified Treatment - Drugs Treatment - Drugs Intervention group: Patients in the first intervention group consume 1.5 cc of minoxidil solution, each solution equivalent to 20 drops twice a day for 6 months. Intervention group: Patients in the second intervention group consume a combination of latanoprost 0.005% and minoxidil 5% for 6 months. Severity of hair loss. Timepoint: Before and after the intervention. Method of measurement: By a skilled physician based on Hamilton-Norwood for male pattern hair loss. Isfahan University of Medical Sciences Approved 2021-02-24 Ethics Committee of Isfahan University of Medical Sciences Azadi Square, Hezar Jerib Street isfahan Isfehan Iran (Islamic Republic of)